Science to Secure
Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
Aerium is building a pipeline of biologics and small molecule antivirals focused on protecting the world against pandemic and epidemic threats.
Our lead assets are monoclonal antibodies against SARS-CoV-2 with potent neutralizing activity in the laboratory against all variants of concern identified to date, including Delta and Omicron. High resolution structural characterization of the antibodies shows non-overlapping epitopes and a synergistic mechanism of action that makes them potential candidates for the treatment or prophylaxis of COVID-19 and variants that emerge from the currently circulating strains of SARS-CoV-2.
Aerium’s fully integrated discovery platform leverages a broad network of international collaborations and established research infrastructures at leading European institutions. Capabilities include a BSL-3/P3 laboratory for advanced viral assays, Cryo-EM expertise for rapid viral protein characterization, and an antibody discovery platform that has already generated Aerium’s promising lead monoclonal antibodies.